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Introduction:  There  is  an urgent  need  for a new  and  effective  tuberculosis  vaccine  because  BCG  does  not
sufﬁciently  prevent  pulmonary  disease.  IMX313  is  a novel  carrier  protein  designed  to improve  cellular  and
humoral  immunity.  MVA85A-IMX313  is  a novel  vaccine  candidate  designed  to boost  immunity  primed
by  bacillus  Calmette-Guérin  (BCG)  that  has  been  immunogenic  in  pre-clinical  studies.  This is  the  ﬁrst
evaluation  of IMX313  delivered  as  MVA85A-IMX313  in  humans.
Methods:  In this  phase  1,  open-label  ﬁrst-in-human  trial,  30 healthy  previously  BCG-vaccinated  adults
were  enrolled  into  three  treatment  groups  and  vaccinated  with  low  dose  MVA85A-IMX313  (group  A),
standard  dose  MVA85A-IMX313  (group  B),  or MVA85A  (group  C).  Volunteers  were  followed  up for  6
months  for  safety  and  immunogenicity  assessment.
Results: The  majority  of  adverse  events  were  mild and  there  were  no  vaccine-related  serious  AEs. Both
MVA85A-IMX313  and  MVA85A  induced  a signiﬁcant  increase  in  IFN-  ELISpot  responses.  There  were  no
signiﬁcant  differences  between  the  Ag85A  ELISpot  and  intracellular  cytokine  responses  between  the  two
study  groups  B (MVA85A-IMX313)  and  C (MVA85A)  at any  time  point  post-vaccination.
Conclusion:  MVA85A-IMX313  was well tolerated  and  immunogenic.  There  was  no  signiﬁcant  difference
in  the  number  of  vaccine-related,  local  or systemic  adverse  reactions  between  MVA85A  and  MVA85A-
IMX313  groups.  The  mycobacteria-speciﬁc  cellular  immune  responses  induced  by  MVA85A-IMX313  were
not signiﬁcantly  different  to those  detected  in the  MVA85A  group.  In  light of  this  encouraging  safety  data,
further  work  to  improve  the  potency  of  molecular  adjuvants  like  IMX313  is  merited.
This  trial  was  registered  on  clinicatrials.gov  ref. NCT01879163.
©  2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. IntroductionThe lack of a safe and effective tuberculosis (TB) vaccine is a
ublic health emergency. TB causes a major global health burden,
ith an estimated 9.0 million incident cases and 1.5 million deaths
∗ Corresponding author at: The Jenner Institute, Old Road Campus Research Build-
ng, Roosevelt Drive, Oxford OX3 7DQ, UK. Tel.: +44 1865 617606;
ax: +44 1865 617608.
E-mail address: helen.mcshane@ndm.ox.ac.uk (H. McShane).
1 Joint ﬁrst authors.
ttp://dx.doi.org/10.1016/j.vaccine.2016.01.062
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
each year [1]. In addition, the emergence of drug resistant forms
of TB further magniﬁes the difﬁculty of TB control. The only cur-
rently available licensed vaccine is Mycobacterium bovis (M. bovis)
bacillus Calmette-Guérin (BCG). BCG prevents disseminated dis-
ease in childhood [2,3], but does not provide sufﬁcient or consistent
protection against pulmonary TB [3–5]. It confers varying effec-
tiveness across different populations for reasons that are not well
understood. An improved TB vaccine is urgently required.Technologies that increase vaccine immunogenicity and effec-
tiveness are critical to achieving this goal. One example is the
immunogenicity-enhancing protein technology, IMX313. IMX313
is a small protein domain that self-assembles into a nanoparticle
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ith seven identical chains. The 55 amino acid sequence is a hybrid
f the oligomerisation domains of two chicken C4b-binding pro-
eins, both distant homologues of human Complement 4 binding
rotein (C4bp) [6]. In pre-clinical studies, IMX313 has an adjuvant-
ike effect when fused with protein antigens [6]. Here we assess the
afety and immunogenicity of IMX313 with a clinically advanced
andidate TB vaccine – Modiﬁed Vaccinia virus Ankara expressing
he immunodominant Mycobacterium.tuberculosis (M.tb) antigen
5A, MVA85A.
MVA85A was designed to boost BCG induced protection and is
he only TB subunit vaccine to be evaluated in an efﬁcacy trial.
n phase I trials, MVA85A was highly immunogenic and induced
otent Ag85A speciﬁc CD4+ T-cell responses in BCG-vaccinated
dults [7–9]. Despite this, in a South African phase IIb trial in 2797
outh African, BCG-vaccinated infants, MVA85A was  safe, but did
ot improve protective efﬁcacy above the level achieved by BCG
lone [10]. The reasons for this could be manifold, but one hypoth-
sis is that MVA85A elicited insufﬁcient IFN--producing T helper
Th1) and/or IL-17-producing CD4+ (Th17) cell responses. After vac-
ination with MVA85A there was only a modest induction of Th1
nd Th17 antigen speciﬁc T-cell responses, which was  10-fold lower
han that seen in UK adults [9].
Efforts to improve the immunogenicity of MVA85A are ongo-
ng. In one strategy, MVA85A has been combined with IMX313. In
oth mice and non-human primate studies IMX313 improved the
mmunogenicity of MVA85A [11]. Here we describe the ﬁrst clin-
cal evaluation of IMX313, administered as MVA85A-IMX313, and
ompared the safety and immunogenicity proﬁle with MVA85A in
 phase I trial in BCG-vaccinated UK adults.
. Methods
.1. Study design
We  undertook a phase I, randomised, open-label, ﬁrst-in-human
linical trial in 30 BCG-vaccinated adults to assess the safety and
mmunogenicity of a candidate TB vaccine, MVA85A-IMX313.
We enrolled volunteers following their written informed con-
ent under a protocol approved by the UK Medicines and Healthcare
roducts Regulatory Agency (EudraCT 2013-000678-31) and the
RES South Central – Oxford Research Ethics Committee (ref.
3/SC/0207). Recruitment took place at the Centre for Clinical Vac-
inology and Tropical Medicine, Oxford, and the NIHR Wellcome
rust Clinical Research Facility, Birmingham. This trial was regis-
ered on clinicatrials.gov (ref. NCT01879163) and was  conducted
ccording to the principles of the Declaration of Helsinki and Good
linical Practice.
.2. Participants
We  enrolled volunteers from the general population around
xford and Birmingham. Volunteers were healthy, aged between
8 and 55 and had received BCG at least 6 months prior to their
ate of enrolment. They had normal baseline haematology and bio-
hemistry and were hepatitis B, C and HIV negative. Latent M.tb
nfection was excluded by a negative ex vivo IFN- ELISpot response
o M.tb early secreted antigenic target 6 kDa (ESAT6) and the 10-
Da culture ﬁltrate protein (CFP10) peptides. The full inclusion and
xclusion criteria are described in Supplementary Methods 1.
.3. VaccinesClinical-grade MVA85A (lot number 0050811) was constructed
s previously described [12]. MVA85A-IMX313 (lot number
010812), which expresses the IMX313 fusion protein, was  con-
tructed as described elsewhere [11]. Both vaccines were produced 34 (2016) 1412–1421 1413
under Good Manufacturing Practice conditions (GMP) by IDT
Biologika GmbH, Germany (IDT).
2.4. Clinical procedures
The ﬁrst 6 volunteers were assigned to the starter group
(group A), who were administered a low dose of MVA85A-IMX313
(1 × 107 pfu) delivered intradermally in a volume of 150 L into the
upper arm (all injections were administered by a 29G diameter,
12.7 mm length needle). These group A (low dose MVA85A-
IMX313) vaccinations occurred step-wise in order to assess safety.
The safety of the ﬁrst volunteer was assessed and 48 h passed before
the next two  volunteers in group A were vaccinated. The remaining
volunteers in group A were vaccinated once the Chief Investigator
decided it was safe to proceed. Once all 6 volunteers in group A had
been followed up for 14 days, the dose was  escalated to 5 × 107 pfu.
One volunteer (the ﬁrst group B volunteer) was assigned to receive
the higher dose MVA85A-IMX313 (5 × 107 pfu, delivered intra-
dermally in a volume of 76 L) and 48 h after vaccination their
safety was  reviewed before we proceeded to randomisation of the
remaining 23 volunteers.
We  randomly allocated the remaining 23 eligible volunteers
(1:1) to receive intradermal MVA85A-IMX313, 5 × 107 pfu (Group
B) or intradermal MVA85A, 5 × 107 pfu, delivered in a volume
of 60 L (Group C). Randomisation was done with sequentially
numbered, opaque, sealed envelopes, prepared by an independent
statistician, opened by the study clinician at enrolment. Volunteers
and laboratory staff were blinded to intervention assignment.
Following vaccination and safety reviews at 30 and 60 min,
all volunteers were followed up for a period of 6 months, with
clinic visits at days 2, 7, 14, 28, 84 and 168. Volunteers completed
diary-cards for the recording of adverse events (AEs) for 7 days
post-vaccination. Symptoms were reviewed at each clinic visit, and
vaccination site observations (redness, swelling) and vital signs
(blood pressure, heart rate, oral or tympanic temperature) were
recorded. Safety bloods (full blood count, urea and electrolytes, liver
enzymes) were collected on D7 and D84 post-vaccination. Solicited
(local injection site: pain, redness, swelling, warmth, itch, scaling;
and systemic: documented fever, feverishness, malaise, arthral-
gia, headache, myalgia, nausea/vomiting, fatigue) and unsolicited
AEs were recorded in line-listings for later analysis. Assignment
of a causal relationship for AEs was conducted according to pre-
deﬁned criteria speciﬁed in the protocol. Blood for immunological
assessment was  taken at all follow-up visits and peripheral blood
mononuclear cells (PBMC) and serum were isolated and cryopres-
erved.
2.5. Immunological evaluations
2.5.1. Ex vivo IFN Enzyme-Linked ImmunoSpot (ELISpot) assay
ELISpot assays were performed on freshly isolated PBMC, from
all volunteers at screening or on day of vaccination and on days 7,
14, 28, 84 and 168 post-vaccination, as previously described [13].
Ag85A single pool of 66-peptides (Peptide Protein Research (PPR),
UK), IMX313 peptides and C4bp (IMAXIO, France) were all used at
a ﬁnal concentration of 2 g/ml. Puriﬁed protein derivative (PPD),
(Statens Serum Institute, Denmark) was  used at 20 g/ml.
ELISpot plates (Millipore) were coated with capture mAb  then
incubated overnight at 4 ◦C. 3 × 105 PBMC were incubated for
18–20 h at 37 ◦C/5% CO2 with Ag85A (single pool of 66 15mer pep-
tides, overlapping by 10 amino acids) (PPR, UK), puriﬁed protein
derivative (PPD) (Staten Serum Institute, Denmark), MVA  CD4 and
CD8T cell epitopes (PPR, UK), IMX313 (IMAXIO, France) and hC4bp
(provided by Anna Blom, Sweden). Staphylococcal enterotoxin B
(Sigma) was  used as a positive control and unstimulated PBMC were
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sed as negative controls. Antigen-speciﬁc background subtracted
esults are presented as spot-forming cells (SFC) per million PBMC.
.5.2. Whole Blood (WB) Intracellular Cytokine Staining (ICS)
Ag85A-speciﬁc intracellular cytokines were measured in WB
amples as previously described [14]. Blood samples were stimu-
ated with Ag85A peptides, or SEB (Sigma–Aldrich), or left without
timulation as a negative control. CD28 and CD49d (BD) were
sed as co-stimulatory antibodies and samples were incubated at
7 ◦C/5% CO2 for 6 h. Following this, Brefeldin A (Sigma–Aldrich)
as added before a further 6 h incubation. Samples were then
reated with 2 mM EDTA (GIBCO). Red blood cells were lysed using
ACS Lysing solution (BD) and samples were frozen for batched ICS
nalysis.
Stimulated and ﬁxed WB  samples were permeabilised and
ncubated with antibodies against: CD3 (AF700), IFN- (PE-Cy7)
Ebioscience), CD4 (Paciﬁc Blue), TNF-  ˛ (APC), IL-17 (AF488) (Biole-
end), CD14 and CD19 (ECD), IL-2 (PE) (Beckman Coulter) and CD8
APC-H7) (BD). Samples were acquired on LSRII (Becton Dickin-
on). Cytokines were measured in singlet CD14−CD19−CD3+, CD4+
r CD8+ T cells. Results are presented as percentages of antigen-
peciﬁc cells producing cytokines minus responses measured in
nstimulated cells. Data was analysed using FlowJo (Tree Star Inc.,
SA), and polyfunctional cytokine immune responses were ana-
ysed using Spice software (http://exon.niaid.nih.gov/spice/).
.5.3. Antibody Enzyme Linked Immunosorbent assay (ELISA)
Levels of Immunoglobulin G (IgG) were measured in serum
amples collected on days 0, 14 and 28 as previously described
15]. Insert-speciﬁc IgG responses were measured to recombinant
g85A (Lionex, Germany). Anti-vector IgG responses were mea-
ured to wild-type MVA  (Vector Core Facility, Jenner Institute,
xford), IMX313 (IMAXIO, France) and hC4bp proteins (provided
y Anna Blom, Sweden). Results are presented as fold change in
ntigen-speciﬁc response of IgG (Optical Density OD) from the
alue at D0.
ig. 1. Study proﬁle. CONSORT ﬂow diagram showing volunteer recruitment and follow u
afety  data was  reviewed, one volunteer was then allocated to group B (5 × 107 pfu intra
ata,  the remaining 23 volunteers were randomised 1:1 to groups B and C (5 × 107 pfu in 34 (2016) 1412–1421
IgG subclasses levels to 85A or IMX313 antigen were determined
in the sera by an indirect plate ELISA. The wells of ELISA plates
(Nunc) were sensitised with Ag85A, IMX313 and hC4bp proteins
(100 L/well in carbonate buffer pH 9.6 at 4 ◦C, overnight), fol-
lowed by blocking with 10% bovine foetal serum (non-USA origin,
sterile-ﬁltered, Sigma) in PBS (pH 7.4) for 2 h at room tempera-
ture. Plates were washed twice with PBS containing 0.05% Tween
20 (PBS/T), followed by addition of 100 L/well of optimally diluted
sera (1/50), in duplicate wells. Plates were incubated at 37 ◦C for
1 h, then washed three times with PBS/T. After washing, 100 L of
optimally diluted (1/1000) anti-human IgG peroxidase conjugate
(anti-human IgG1, anti-human IgG2, anti-human IgG3, anti-human
IgG4, Fisher Scientiﬁc) in FBS-PBS was  added to each well. Plates
were incubated for 1 h at 37 ◦C, then washed ﬁve times with PBS/T
before the addition of 100 L per well of TMB HRP Substrate
for ELISA (UP664780, Interchim). The reaction was stopped after
20 min  with 2 N H2SO4, and OD values were read at 405 nm.  Results
are presented as fold change in OD from the value at Day 0.
All serum samples from each volunteer were run on the same
ELISA plate to control for assay variability. A pool of Ag85A-positive
sera was  included in all plates.
2.6. Statistical analysis
All volunteers were randomised and vaccinated according to
protocol, and so our analyses were per protocol.
The primary study outcome was safety as assessed by the fre-
quency and severity of vaccine-related local and systemic AEs.
Safety data was  summarised by frequency and severity of AEs
using descriptive statistics. Statistical analyses to compare the
standard dose groups were performed using GraphPad Prism. The
Mann–Whitney U-test was used to determine differences between
groups.
The secondary study outcome was  immunogenicity. ELISpot,
WB ICS and antibody response statistical analyses were performed
using GraphPad Prism. The Mann–Whitney U-test and unpaired
p. Group A (1 × 107 pfu intradermal MVA85A-IMX313) was fully enrolled ﬁrst. Once
dermal MVA85A-IMX313). Following another planned pause for a review of safety
tradermal MVA85A).
accine 34 (2016) 1412–1421 1415
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Table 2
Related adverse events. Shown are the local and systemic adverse events (AE) that
occurred following vaccination. Frequency is calculated as the number of volunteers
counted once at the time of the highest severity grading of the event.
Symptom and intensity A (n = 6) B (n = 12) C (n = 12)
Local
Pain
Mild 4 (67) 8 (67) 10 (83)
Moderate 1 (8)
Severe
Redness
Mild 6 (100) 11 (92) 11 (92)
Moderate 1 (8) 1 (8)
Severe
Swelling
Mild 5 (83) 11 (92) 11 (92)
Moderate 1 (17) 1 (8)
Severe 1 (8)
Warmth
Mild 3 (50) 11 (92) 11 (92)
Moderate 1 (8)
Severe
Itch
Mild 4 (67) 10 (83) 9 (75)
Moderate 1 (17) 1 (8)
Severe
Scaling
Yes 6 (100) 8 (67) 8 (67)
Systemic
Feverishness
Mild 2 (33) 4 (33) 2 (17)
Moderate 2 (17) 1 (8)
Severe
Arthralgia
Mild 2 (17) 3 (25)
Moderate
Severe
Myalgia
Mild 2 (33) 4 (33) 2 (17)
Moderate
Severe
Fatigue
Mild 4 (67) 5 (42) 7 (58)
Moderate 1 (17)
Severe 1 (8)
Headache
Mild 3 (50) 5 (42) 3 (25)
Moderate 1 (17) 3 (25)
Severe
NauseaA. Minhinnick et al. / V
-test were used to determine differences between groups. The
ilcoxon matched pairs signed rank test was used to detect dif-
erences between time points in the same group. Area Under the
urve (AUC) was used to examine overall responses during follow-
p period.
. Results
Between July 17 2013 and July 17 2014, 30 of the 42 volun-
eers screened for eligibility were enrolled in the trial (Fig. 1). The
aseline demographics were similar between groups (Table 1).
.1. Vaccine safety
Group A (the low dose MVA85A-IMX313 safety group) pro-
eeded to completion without safety concerns. The numbers of AEs
onsidered at least possibly related to vaccination were broadly
imilar between groups with medians of 10 in group A (low dose
VA85A-IMX313), 8.5 in group B (MVA85A-IMX313) and 9 in
roup C (MVA85A). There was no statistical difference between
roup B and C (p = 0.5024). All related AEs and their severities are
hown in Table 2. There were no documented temperature rises
ollowing vaccination in any group.
The majority of AEs were mild in nature. There was no signiﬁcant
ifference in the local injection site reaction between groups, with
edian diameters of redness and swelling of 28.5 mm and 9 mm in
roup A (low dose MVA85A-IMX313), 40 mm and 11.5 mm in group
 (MVA-IMX313) and 32 mm and 14 mm in group C (MVA85A).
here was no statistical difference between group B and group C
ith p values of 0.1236 (redness) and 0.6430 (swelling) (Fig. 2).
here were four severe AEs that were considered possibly related
o vaccination (3 in a group B, MVA85A-IMX313 volunteer and 1
n a group C, MVA85A volunteer). The group B (MVA85A-IMX313)
olunteer reported severe nausea from D2 to D3, severe malaise
rom D2 to D4 and severe fatigue from D2 to D4 following vacci-
ation. The volunteer from group C (MVA85A) had vaccination site
welling that met  the criteria for a severe AE that peaked at 60 mm
iameter on D4 post-vaccination.
There was one laboratory AE considered related to vaccination.
 group C (MVA85A) volunteer had a mildly raised alanine trans-
erase at screening and D7 post-vaccination, which was moderately
levated at D28, mildly elevated at D84 and normalised by D168
ost-vaccination. The volunteer was asymptomatic and the AE was
onsidered possibly related to vaccination.
There was  one unrelated serious AE reported in the study in a
roup B (MVA85A-IMX313) volunteer who was admitted overnight
o hospital for investigation of chest pain 157 days after vaccination
ith MVA85A-IMX313. There were no other serious AEs.
able 1
emographics. Baseline demographics of all study participants by group. Age and
ime interval since BCG: Means were compared by one-way Anova with Tukey’s test
or  multiple comparisons. No signiﬁcant difference was  observed between groups
 > 0.05.
Group A
(n = 6)
Group B
(n = 12)
Group C
(n = 12)
Age
Mean age, years (range) 29.1 (23–42) 34.7 (19–50) 34.7 (20–55)
Sex
Female, n (%) 5 (83) 8 (67) 6 (50)
Place of birth
Europe 6 12 12
Time interval since BCG
Mean time, years (range) 17.0 (9–28) 24.4 (12–38) 24.8 (1–42)
Mild 2 (33) 2 (17) 3 (25)
Moderate
Severe 1 (8)
Malaise
Mild 4 (67) 2 (17)
Moderate 1 (8) 2 (17)
Severe 1 (8)
Other
Mild 1a (17) 1b (8) 2c (16)
Moderate 3d (25)
Severe
a One group A (low dose MVA85A-IMX313) volunteer had 2 mild ‘other’ AEs: they
reported feeling ‘disconnected, hazy and sluggish’ on D2, and having ‘non-speciﬁc
dizziness’ from D0 to D2.
b One group B (MVA85A-IMX313) volunteer had 2 mild ‘other’ AEs: they reported
cold symptoms from D6-10 and an ‘upset tummy’ on D1.
c 2 group C (MVA85A) volunteers had mild ‘other’ AEs. One volunteer reported
ipsilateral axillary tenderness from D1 to D11, another volunteer reported light-
headedness on the day of vaccination and ipsilateral axillary tenderness on D4-6.
d 3 group C (MVA85A) volunteers had moderate ‘other’ AEs. One volunteer had a
mildly raised alanine transferase at screening and D7 post-vaccination, which was
moderately elevated at D28, mildly elevated at D84 and normalised by D168 post-
vaccination. Another volunteer reported cold/ﬂu symptoms from D1 to D6. Another
volunteer reported ipsilateral axillary tenderness from D2 to D17.
1416 A. Minhinnick et al. / Vaccine 34 (2016) 1412–1421
Fig. 2. Local reactogenicity. Maximum diameter of redness (A) and swelling (B) at challenge site with median and IQR (dots represent individual volunteers). Medians were
compared with the Mann–Whitney U-test. The difference in median diameter was  not statistically signiﬁcant between groups (p > 0.05).
Fig. 3. Ex vivo PBMC IFN- ELISpot responses to Ag85A pool of 66 peptides (A), PPD (B), MVA peptides for CD4 (C), and CD8 epitopes (D) in BCG-vaccinated healthy UK adults
boosted with either MVA85A-IMX313 or MVA85A (5 × 107 pfu). Box and whisker plots show median, inter-quartile range, minimum and maximum values. The Wilcoxon
matched pairs signed rank test was used to detect differences between time points in the same group and p-values have not been adjusted for multiple comparisons. There
were  no signiﬁcant differences in the overall antigen-speciﬁc IFN- responses between the two  study groups (Mann–Whitney test for AUC, p = 0.5059, p = 0.5059, p = 0.2721
and  p = 0.1585 for Ag85A-, PPD-, MVA  (CD4)- or MVA  (CD8)-speciﬁc responses respectively).
A. Minhinnick et al. / Vaccine 34 (2016) 1412–1421 1417
Fig. 4. Whole blood ICS Ag85A-speciﬁc responses in volunteers vaccinated with MVA85A-IMX313 or MVA85A (5 × 107 pfu) at baseline, day 7 and day 168. Percentages of CD4+
T cells producing cytokines are shown in ﬁgures (A–D). Lines show median responses in each group, whiskers show inter-quartile range. The Wilcoxon matched pairs signed
rank  test was used to detect differences between time points in the same group and p-values have not been adjusted for multiple comparisons. No signiﬁcant differences
in  percentages of cells producing IFN- , TNF-˛, IL-2 and IL-17 were detected between the two  groups (Mann–Whitney test for AUC, p = 0.4799, p = 0.5987, p = 0.5575 and
p
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p = 0.3241 for CD4+ T cells IFN- , TNF-˛, IL-2 and IL-17 respectively).
.2. Vaccine immunogenicity
.2.1. MVA85A and MVA85A-IMX313 induces
ycobacteria-speciﬁc ex vivo IFN- ELISpot responses
At the low dose (107 pfu MVA85A-IMX313) the vaccine induced
igniﬁcant Ag85A-speciﬁc IFN- ELISpot responses that peaked at
7 post-vaccination (median = 384 SFC/106 PBMC) and remained
igniﬁcant up to D84 post-vaccination. Signiﬁcantly increased PPD
FN- responses (median = 447 SFC/106 PBMC) were detected at D7
ost-vaccination (data not shown).
Vaccination of BCG-primed UK adults with MVA85A-IMX313
r MVA85A, both at 5 × 107 pfu, induced a signiﬁcant increase
n Ag85A-speciﬁc IFN- responses that was durable up to 6
onths following vaccination. These responses peaked at D7 post-
accination with a median IFN- response of 515 SFC/106 PBMC
n the MVA85A-IMX313 group compared to 1107.5 SFC/106 PBMC
n the MVA85A group (Fig. 3A). There were no signiﬁcant differ-
nces between the Ag85A ELISpot responses in the two  groups
 (MVA85A-IMX313) and C (MVA85A) at any time point post-
accination, or in the overall Ag85A-speciﬁc IFN- response (AUC,
 = 0.5059).
There was a signiﬁcant increase in PPD-speciﬁc IFN- ELISpot
esponses in both groups at D7 in comparison to baseline
ith a median IFN- response of 542.5 SFC/106 PBMC in
roup B (MVA85A-IMX313) and 780 SFC/106 PBMC in group C
MVA85A) (Fig. 3B). The PPD response was not signiﬁcantly dif-
erent between the MVA85A-IMX313 and MVA85A groups (AUC,
 = 0.5059).ELISpot IFN- responses to MVA  CD4+ T cell epitopes peaked at
D14 post-vaccination, with median responses of 19 SFC/106 PBMC
in group B (MVA85A-IMX313) and 31 SFC/106 PBMC in group C
(MVA85A) (Fig. 3C). ELISpot responses to MVA  CD8+ T cell epitopes
were signiﬁcantly induced in both groups and these responses also
peaked at D14 with a median response of 117 SFC/106 PBMC in
group B (MVA85A-IMX313) and 282 SFC/106 PBMC in group C
(MVA85A), remaining signiﬁcantly increased until D28. There were
no signiﬁcant differences in responses to MVA  epitopes between
the two  study groups (AUC, p = 0.2721 and p = 0.1585 for MVA
CD4+ T cells epitopes and MVA  CD8+ T cells epitopes respectively)
(Fig. 3D).
Vaccination with MVA85A-IMX313 or MVA85A alone did
not induce ELISpot responses to IMX313 or C4bp peptides
(Supplementary Material 1).
3.2.2. Total whole blood intracellular cytokine response
Intracellular Ag85A-speciﬁc IFN- , TNF-˛, IL-2 and IL-17 were
examined in stimulated whole blood from volunteers in the two
study groups B (MVA85A-IMX313) and C (MVA85A) at baseline, D7
and D168 post-vaccination. No signiﬁcant differences in percent-
ages of cells producing IFN- , TNF-˛, IL-2 and IL-17 were detected
between the two  groups (AUC, p = 0.4799, p = 0.5987, p = 0.5575,
p = 0.3241, p = 0.6943 and p = 0.8325 for CD4+ T cells IFN- , TNF-
˛, IL-2 and IL-17 and CD8+ T cells IFN- and TNF-˛, respectively)
(Fig. 4).
CD4+ T cell IFN- and IL-2 signiﬁcantly increased in both groups
at D7 and D168 (Fig. 4A and C). Group B (MVA85A-IMX313)
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Fig. 5. Polyfunctionality of Ag85A-speciﬁc CD4+ T cells in volunteers vaccinated with MVA85A-IMX313 or MVA85A (5 × 107 pfu). Percentages of CD4+ T cells simultaneously
producing IFN- , TNF-  ˛ and IL-2 (A) and those double positive for IFN- and TNF-  ˛ are shown in (B). Box and whisker plots show minimum and maximum values with
horizontal lines representing medians. The Wilcoxon matched pairs signed rank test was used to detect differences between time points in the same group and p-values have
not  been adjusted for multiple comparisons. No signiﬁcant differences in percentages of CD4+ T cells simultaneously producing IFN- , TNF-  ˛ and IL-2 or double positive for
IFN-  and TNF-  ˛ were detected between the two  groups (Mann–Whitney test for AUC, p = 0.863 and p = 0.518, respectively).
Fig. 6. Serum antibody response to Ag85A (A), Wild-type MVA  (B), IMX313 (C) and C4bp (D) in the MVA85A and MVA85A-IM313 vaccine groups. Data is presented as fold
c asured
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change responses calculated by dividing each time point’s antibody response (me
as  used to detect differences between the two study groups.
olunteers had signiﬁcantly higher percentages of CD4+ TNF-˛+
 cells at D7 and D168 compared to baseline. A signiﬁcant increase
n percentages of CD4+ T cells producing TNF-  ˛ was detected in
roup C (MVA85A) at D168 (Fig. 4B). Ag85A-speciﬁc IL-17+ CD4+ T
ell responses were detectable following vaccination in both study in optical density) by its corresponding day 0 response. The Mann–Whitney test
groups (Fig. 4D). CD8+ T cells producing IFN- and TNF-  ˛ were
detected at very low percentages in both groups B (median D7
responses of 0.006 and 0.005 for CD8+IFN-+ and CD8+TNF-˛+
respectively) and C (median D7 responses of 0.003 and 0.0027 for
CD8+IFN-+ and CD8+TNF-˛+ respectively) (data not shown).
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Fig. 7. Serum IgG subclass responses to Ag85A (A) and IMX313 (B) in the MVA85A-IMX313 and MVA85A vaccine groups (5 × 107 pfu). Data is measured in optical density
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y  its corresponding day 0 response. Unpaired t test was  used to compare between
We  focussed on the dominant functional phenotypes and
ound polyfunctional CD4+ T cells, making two  or more cytokines
imultaneously, cells producing IFN- in combination with TNF-
 and IL-2 (Fig. 5A) or double positive for IFN- and TNF-˛
Fig. 5B) were all induced following MVA85A-IMX313 or MVA85A
accination. The magnitude of these responses was not signif-
cantly different between the two study groups (AUC p = 0.863
nd p = 0.518 for CD4+ T cells simultaneously producing IFN-
, TNF-  ˛ or double positive for IFN- and TNF-  ˛ respectively
Mann–Whitney)) (Fig. 5). No polyfunctional CD8+ T cells were
etected.
.2.3. Serum IgG responses after MVA85A-IMX313 and MVA85A
accination
Levels of serum IgG were assessed in volunteers in the MVA85A-
MX313 and MVA85A (both at 5 × 107 pfu) study groups. There was
n increase in serum Ag85A-IgG at D28 in both groups. MVA85A-
MX313 vaccination induced a median OD 405 nm fold change
f 1.640 in group B volunteers and MVA85A vaccination induced
 median OD 405 nm fold change of 1.227 in group C volun-
eers (Fig. 6A). These responses were not different between groups
p = 0.343). When individual IgG subclasses were examined, in both
roups IgG1 responses to Ag85A increased at D28 post-vaccination
n both groups (median OD 405 nm fold change = 2.19 and 1.83 in
roup B and C, respectively). Ag85A-speciﬁc IgG2 increased in the
VA85A-IMX313 group with a median OD 405 nm fold change of
.355. Other 85A-speciﬁc IgG subclasses responses did were not
nduced (Fig. 7A).
Anti-MVA IgG was detected in both groups at D14 and D28 post-
accination. Group B median OD 405 nm fold change was  3.966 at
14 and 4.506 at D28 compared to group C median OD 405 nm
old change of 2.347 at D14 and 2.891 at D28. No differences were
etected in MVA-speciﬁc IgG responses between the two  study
roups (Fig. 6B).
IMX313-speciﬁc IgG responses were detectable in the MVA85A-
MX313 vaccination group (B) at D14 post-vaccination and
igniﬁcantly increased at D28 (p = 0.0028). As expected, these
esponses were not detected in the MVA85A alone group (C)
Fig. 6C). When IgG subclasses were examined, the IMX313-speciﬁc
gG responses in the MVA85A-IMX313 Group (B) were mainly IgG1
Fig. 7B). There were no detectable responses to human C4bp at any
ime point post-vaccination (Fig. 6D).lated by dividing each time point’s antibody response (measured in optical density)
s.
4. Discussion
In this phase I clinical trial we  assessed the safety and adjuvant
effect of IMX313, which was delivered for the ﬁrst time to humans,
as MVA85A-IMX313.
We demonstrated that this vaccine was well tolerated. The
adverse event proﬁles of both MVA85A-IMX313 and MVA85A were
similar and acceptable. Importantly, there were no documented
high temperatures in any volunteers. The only severe systemic AEs
considered possibly related to vaccination were in a group B volun-
teer who  developed nausea, fatigue and malaise during a diarrhoeal
illness that her family also became unwell with. These AEs were
included in the analysis because it was  not possible to fully dis-
tinguish symptoms that were potentially related to the vaccine
from symptoms arising from the volunteer’s probably infectious
pathology.
In this study we show that both MVA85A and MVA85A-IMX313
signiﬁcantly induce mycobacteria-speciﬁc immune responses. At
the peak time point 1 week post-vaccination both vaccines induced
Ag85A-speciﬁc IFN- ELISpot responses that were not signiﬁcantly
different. This ﬁnding is in contrast with previously published data
comparing the same vaccines in animal models, where MVA85A-
IMX313 was more immunogenic than MVA85A [11]. This may
be due to differences in vaccine regime, dose and/or species. In
mice and non-human primates that had not received a prior BCG
immunisation, two doses of MVA85A-IMX313 were required to
demonstrate a signiﬁcant enhancement of immune responses over
MVA85A [12].
It has previously been shown that anti-vector immunity
can interfere with insert-induced responses [16]. We  studied
vaccine-induced cellular anti-vector immunity and demonstrated
that both studied vaccines induced comparable anti-MVA T cell
responses.
Intracellular whole blood cytokines were comparable between
the two study groups and polyfunctional CD4+ T cells were induced
by both vaccines. While there are no deﬁned correlates of protec-
tion against TB, work on a Leishmania major pre-clinical model has
demonstrated the importance of the quality of vaccine-induced
T cells as measured by cytokines polyfunctionality in protection
[17,18]. A successful vaccine against TB, might require the induction
of potent polyfunctional T cells. In the present study we could detect
vaccine-induced CD4+ T cells that can simultaneously make IFN- ,
TNF-˛ and IL-2 as well as those double positive for IFN- and TNF-˛.
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owever, the role of these cells in protection against M.tb remains
o be investigated. The functional quality of these vaccine-induced
D4+ T cells was not enhanced by fusion to IMX313.
We  detected comparable increased levels of anti-85A IgG in
oth study groups. These responses were predominantly IgG1,
nd the fold change IgG1 responses were higher in the MVA85A-
MX313 group than after MVA85A. The role of humoral immunity
s increasingly recognised as important in TB vaccine develop-
ent. It was previously shown that mycobacteria-speciﬁc human
gG could modulate both cellular and humoral immune responses
o mycobacteria [19] [20]. IgG1 was reported to be the pre-
ominant antibody Isotype present in sera of TB Patients [21].
ussein et al. [22] suggested a role of IgG1 in TB by enhanc-
ng release of TNF-  ˛ in active patients. It was suggested that
he presence of IgG1 and IgG3 antibodies might enhance bac-
erial uptake and clearance of pathogen via macrophages Fc
eceptor [22].
In this trial, both vaccine groups had a comparable increase in
erum MVA-speciﬁc IgG, while IgG responses to IMX313 increased
n the MVA85A-IMX313 group and were not detectable in the
VA85A group. The role of these antibody responses is unclear
nd needs to be further investigated. No antibody cross-reactivity
as detected in any of the study groups to the oligomerisation
omain of human C4bp, which is likely due to the limited similarity
etween the IMX313 and human C4bp [11].
Following the failure of MVA85A to enhance efﬁcacy in BCG-
accinated South African infants [10], there has been a refocussing
f efforts to develop a diverse range of potent candidate TB vaccines.
hese approaches include the inclusion of technologies to enhance
mmunogenicity, novel antigen delivery systems that induce dif-
erent phenotypes of T cells, novel routes of immunisation and the
ssessment of novel candidate antigens. It is likely that multiple
pproaches will be required.
. Conclusion
Given the encouraging safety data in this study, future research
ptimising molecular proteins for further evaluation in recom-
inant viral vectors is warranted. This research may  have the
otential to accelerate not only TB vaccine development, but
lso that of other pathogens of global importance including HIV,
nﬂuenza, Staphylococcus aureus and malaria.
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